\
&
Contact us
\
&
Contact us
Published on | 4 months ago
Programmes ERCThe ERC is dedicated to funding frontier research that explores uncharted territories, fosters interdisciplinary collaboration, and pushes the boundaries of knowledge. This research often leads to valuable insights and practical applications that address complex global challenges, benefiting society as a whole.
Explore the section below to discover how ERC-funded projects transcend the mere advancement of scientific and technological knowledge. This section includes comprehensive reports derived from various analyses outlining how ERC’s portfolio contributes to major EU policy priorities. The groundbreaking research supported by the ERC has nurtured the development of innovative approaches that have the potential to positively impact various aspects of our lives.
Contribution to policies
Exploring ERC Frontier Research
--> A summary of the findings can be found in this ERC press release (July 2022).
Taken from Mapping ERC Frontier Research: an overview (ERC website)
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
